Global H2 Antagonists or H2 blockers Market Insights, Forecast to 2034
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global H2 Antagonists or H2 blockers Market Insights, Forecast to 2034
H2 blockers are a group of medicines that reduce the amount of acid produced by the cells in the lining of the stomach. They are also called 'histamine H2-receptor antagonists' but are commonly called H2 blockers.
Market Analysis and InsightsGlobal H2 Antagonists or H2 blockers Market
Global H2 Antagonists or H2 blockers market is expected to reach to US$ 4120 million in 2024, with a positive growth of %, compared with US$ 4215 million in 2022 which suffered dual impact of COVID-19 and Russia-Ukraine War in the year. Backed with the increasing demand from downstream industries, H2 Antagonists or H2 blockers industry is evaluated to reach US$ 3561.2 million in 2029. The CAGR will be -2.4% during 2024 to 2029.
The Histamine H2-receptor Antagonists market is primarily driven by the need for effective treatments for conditions related to excessive stomach acid production. Histamine H2-receptor antagonists, commonly known as H2 blockers, are medications used to reduce gastric acid secretion and alleviate symptoms of conditions such as gastroesophageal reflux disease (GERD) and peptic ulcers. The increasing prevalence of acid-related disorders, coupled with the rising awareness of their impact on digestive health, contributes to market growth. Moreover, advancements in gastrointestinal medicine and the demonstrated efficacy of H2 blockers in providing symptom relief further propel adoption. However, challenges include optimizing dosing regimens and addressing potential interactions or side effects. Navigating patient-specific treatment needs, ensuring appropriate usage in conjunction with other medications, and managing long-term treatment plans are ongoing concerns. The market's success relies on continuous research into acid-related disorders, collaborations between pharmaceutical manufacturers and healthcare providers, and comprehensive patient education on the benefits and potential risks of H2-receptor antagonist treatments while addressing the evolving challenges associated with digestive health management and treatment accessibility.
Report Covers
This report presents an overview of global H2 Antagonists or H2 blockers market from 2018 to 2029, aiming to help readers to get a comprehensive understanding of global H2 Antagonists or H2 blockers market with multiple angles. Items like regional revenue from 2018 to 2029 and companies’ revenue and gross margin from 2018 to 2024 are analyzed. In addition, revenue of product type and application in each region from 2018 to 2029 are also highlighted.
Companies, Type, Application and Regions Listed in the Report
Takeda
Pfizer
AstraZeneca
Bayer
Sun Pharma
Teva
Eisai Co.
Viatris
AOSAIKANG Pharma
Luoxin Pharma
LIVZON
Eastchina Pharma
Segment by Type
Oral
Injection
Hospital
Drugs Store
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue analysis from 2018 to 2029
Chapter 3Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Product revenue analysis by type from 2018 to 2029 globally
Chapter 5Product revenue analysis by application from 2018 to 2029 globally
Chapter 6Product revenue analysis by type and application from 2018 to 2029 in US & Canada. Product revenue analysis of each country in US & Canada from 2018 to 2029
Chapter 7Product revenue analysis by type and application from 2018 to 2029 in Europe. Product revenue analysis of each country in Europe from 2018 to 2029
Chapter 8Product revenue analysis by type and application from 2018 to 2029 in China. Product revenue analysis of China from 2018 to 2029
Chapter 9Product revenue analysis by type and application from 2018 to 2029 in Asia (excluding China). Product revenue analysis of each country in Asia (excluding China) from 2018 to 2029
Chapter 10Product revenue analysis by type and application from 2018 to 2029 in Middle East, Africa and Latin America. Product revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2029.
Chapter 11Companies’ outline, covering company’s basic information, major business, H2 Antagonists or H2 blockers introduction, etc. H2 Antagonists or H2 blockers Revenue and Gross Margin of each company from 2018 to 2024
Chapter 12Mr Accuracy reports Conclusions of H2 Antagonists or H2 blockers
Chapter 13Methodology and Data Sources adopted by Mr Accuracy reports
Market Analysis and InsightsGlobal H2 Antagonists or H2 blockers Market
Global H2 Antagonists or H2 blockers market is expected to reach to US$ 4120 million in 2024, with a positive growth of %, compared with US$ 4215 million in 2022 which suffered dual impact of COVID-19 and Russia-Ukraine War in the year. Backed with the increasing demand from downstream industries, H2 Antagonists or H2 blockers industry is evaluated to reach US$ 3561.2 million in 2029. The CAGR will be -2.4% during 2024 to 2029.
The Histamine H2-receptor Antagonists market is primarily driven by the need for effective treatments for conditions related to excessive stomach acid production. Histamine H2-receptor antagonists, commonly known as H2 blockers, are medications used to reduce gastric acid secretion and alleviate symptoms of conditions such as gastroesophageal reflux disease (GERD) and peptic ulcers. The increasing prevalence of acid-related disorders, coupled with the rising awareness of their impact on digestive health, contributes to market growth. Moreover, advancements in gastrointestinal medicine and the demonstrated efficacy of H2 blockers in providing symptom relief further propel adoption. However, challenges include optimizing dosing regimens and addressing potential interactions or side effects. Navigating patient-specific treatment needs, ensuring appropriate usage in conjunction with other medications, and managing long-term treatment plans are ongoing concerns. The market's success relies on continuous research into acid-related disorders, collaborations between pharmaceutical manufacturers and healthcare providers, and comprehensive patient education on the benefits and potential risks of H2-receptor antagonist treatments while addressing the evolving challenges associated with digestive health management and treatment accessibility.
Report Covers
This report presents an overview of global H2 Antagonists or H2 blockers market from 2018 to 2029, aiming to help readers to get a comprehensive understanding of global H2 Antagonists or H2 blockers market with multiple angles. Items like regional revenue from 2018 to 2029 and companies’ revenue and gross margin from 2018 to 2024 are analyzed. In addition, revenue of product type and application in each region from 2018 to 2029 are also highlighted.
Companies, Type, Application and Regions Listed in the Report
By Company
Takeda
Pfizer
AstraZeneca
Bayer
Sun Pharma
Teva
Eisai Co.
Viatris
AOSAIKANG Pharma
Luoxin Pharma
LIVZON
Eastchina Pharma
Segment by Type
Oral
Injection
Segment by Application
Hospital
Drugs Store
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter Outline
Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue analysis from 2018 to 2029
Chapter 3Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Product revenue analysis by type from 2018 to 2029 globally
Chapter 5Product revenue analysis by application from 2018 to 2029 globally
Chapter 6Product revenue analysis by type and application from 2018 to 2029 in US & Canada. Product revenue analysis of each country in US & Canada from 2018 to 2029
Chapter 7Product revenue analysis by type and application from 2018 to 2029 in Europe. Product revenue analysis of each country in Europe from 2018 to 2029
Chapter 8Product revenue analysis by type and application from 2018 to 2029 in China. Product revenue analysis of China from 2018 to 2029
Chapter 9Product revenue analysis by type and application from 2018 to 2029 in Asia (excluding China). Product revenue analysis of each country in Asia (excluding China) from 2018 to 2029
Chapter 10Product revenue analysis by type and application from 2018 to 2029 in Middle East, Africa and Latin America. Product revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2029.
Chapter 11Companies’ outline, covering company’s basic information, major business, H2 Antagonists or H2 blockers introduction, etc. H2 Antagonists or H2 blockers Revenue and Gross Margin of each company from 2018 to 2024
Chapter 12Mr Accuracy reports Conclusions of H2 Antagonists or H2 blockers
Chapter 13Methodology and Data Sources adopted by Mr Accuracy reports